TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06447493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: 10 minute rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: 10 minute rest period.
Study: NCT06007859

Intervention type: OTHER
Intervention: section orientation
Description: The patient was placed in a decubitus supine head back extension position to fully expose the cervical thyroid examination site. The instrument was adjusted appropriately to achieve optimal imaging quality, the suspicious nodule was located in conventional ultrasound mode, the SWE option in VT mode was selected, and the patient was instructed to hold his/her breath to minimize the effect of respiration, and elastograms of the nodule in transverse and longitudinal sections were obtained.
Study: NCT05719636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional protocol that involves simple active and passive range of motion exercises of lower limb with positioning for assistive devices was provided

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise
Description: The protocol that was applied on the members of (experimental group) are progressive resistance exercises. These passive resistance exercises included Flexion, Extension, Abduction, Adduction of hip; Flexion, Extension of knee; with minimum time in start and minimum quantity of loads, with Thera bands and sandbags,.
Study: NCT01269398

Intervention type: DEVICE
Group type: OTHER
Intervention: GO-LIF and SpineAssist SYSTEMS
Study: NCT04917510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local block
Description: See control and study arm group descriptions for the local block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local block
Description: See control and study arm group descriptions for the local block
Study: NCT05005559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
Study: NCT05065944

Intervention type: BEHAVIORAL
Intervention: Telemedicine
Description: Pre-anesthesia assessment (history and physical examination) via telemedicine. Intervention is a one-time telemedicine clinic visit for approximately 30 minutes to 1 hour. Individual patients will be randomized to telemedicine and that visit will be scheduled via the Zoom video conferencing platform.

Intervention type: BEHAVIORAL
Intervention: In Person Visit
Description: Pre-anesthesia assessment (history and physical examination) in person at Moffitt Cancer Center (usual care)
Study: NCT04897412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514 Injection
Description: Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (0.9% NaCl) placebo for injection
Study: NCT04728971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin Sodium 50 MG Injection
Description: Give Micafungin 150 mg/d within 24 hours after liver transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin Acetate
Description: Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.
Study: NCT05832424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPLIFT program
Description: The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
Study: NCT06472895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112 monotherapy
Description: A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W
Study: NCT05399758

Intervention type: DEVICE
Intervention: NOL monitor
Description: NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.
Study: NCT05567068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine

Intervention type: DRUG
Group type: OTHER
Intervention: Mesalamine
Description: Mesalamine
Study: NCT04760314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid
Description: Self-applied

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Corticosteroid
Description: Self-applied

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Corticosteroid
Description: Self-applied
Study: NCT05781750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zetomipzomib
Description: Subcutaneous injection of zetomipzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zetomipzomib
Description: Subcutaneous injection of zetomipzomib
Study: NCT05794997

Intervention type: DRUG
Intervention: Propranolol or Carvedilol
Description: Propranolol or Carvedilol claim is used as the exposure group.

Intervention type: DRUG
Intervention: Atenolol, Bisoprolol or Sotalol
Description: Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
Study: NCT04707963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peanut protein powder
Description: Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full body resistance training
Description: Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full body resistance training
Description: Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
Study: NCT06000579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFT
Description: Each student will be asked to voluntarily give their phone number and last menstrual cycle date, and the day will be determined for the first session. Then, the first EFT session will be made by the researchers by calling 14 days before the menstruation date. In the 2nd and 3rd sessions, a total of 3 sessions of EFT will be applied face-to-face by the researchers 14 days before menstruation. After each student completes three menstrual cycles, the researchers will meet with the student and PMSS will be applied as a post-test.
Study: NCT06381323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: All eligible subjects enter a 2-week enrollment phase and only take stable doses of controlled-release nifedipine. After completing baseline examinations, subjects with SBP \<180 and ≥140 mmHg and DBP \<120 and ≥90 mmHg enter the follow-up phase of the treatment period. Eligible subjects receive a starting dose of 20 mg qd of Finerenone. If the blood pressure is still ≥140/90 mmHg at week 4, serum potassium is \<5.0 mmol/L, and eGFR has decreased \<30% compared to baseline, the Finerenone dose is adjusted to 40 mg qd.
Study: NCT06376669

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Stereotactic Body Radiation therapy (SBRT)
Description: Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks
Study: NCT05781750

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injection of placebo
Study: NCT06521593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applying a tourniquet for either a short or long time during total knee replacement
Description: All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation while in group two who underwent short duration application of a tourniquet, the tourniquet was only applied just before cementation, was inflated also to 150 mmHg above the systolic blood pressure of the patients, and was deflated after bone cementation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Applying a tourniquet for either a short or long time during total knee replacement
Description: All patients underwent spinal anesthesia and the tourniquet was applied to the middle of the thigh; in group one who underwent long-duration application of a tourniquet, it was applied only before the skin incision by inflating it to 150 mmHg above the systolic blood pressure of the patients and deflation finishing of bone cementation while in group two who underwent short duration application of a tourniquet, the tourniquet was only applied just before cementation, was inflated also to 150 mmHg above the systolic blood pressure of the patients, and was deflated after bone cementation.
Study: NCT04709757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Dosing HF10 30/90
Description: 10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Dosing HF10 30/360
Description: 10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
Study: NCT05497557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole will be administered as an oral capsule.
Study: NCT04991597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Compress Pack
Description: Palmar aspect of forearm will have a cold compress pack placed on it.
Study: NCT05347589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises
Description: Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation of the Quadratus lumborum
Description: Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
Study: NCT04991597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Compress Pack
Description: Palmar aspect of forearm will have a cold compress pack placed on it.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Temperature Compress Pack
Description: Palmar aspect of forearm will have a room temperature compress pack placed on it.
Study: NCT05347589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post isometric relaxation of the Quadratus lumborum
Description: Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
Study: NCT05009472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: expander with deferential opening and petit face mask
Description: bonded expander with two screws and vertical hooks for attachment face mask. adjustment face mask with forehead and chin anchorage
Study: NCT05776186

Intervention type: DRUG
Intervention: Spinal anesthesia with heavy bupivacaine
Description: Spinal anesthesia

Intervention type: DRUG
Intervention: Spinal anesthesia with heavy bupivacaine
Description: Spinal anesthesia
Study: NCT04991597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Temperature Compress Pack
Description: Palmar aspect of forearm will have a room temperature compress pack placed on it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
Study: NCT05497557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered as an oral tablet.
Study: NCT04971512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-721
Description: Oral administration (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-721
Description: Oral administration (Part 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: Placebo to match EDP-721, oral administration (Part 1)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: Placebo to match EDP-721, oral administration (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-721 (Part 2)
Description: Oral administration (Part 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: Placebo to match EDP-721 (Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral administration
Study: NCT05691569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: doll therapy
Description: empathy dolls

Intervention type: OTHER
Group type: OTHER
Intervention: doll therapy
Description: empathy dolls
Study: NCT06569277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mobile application
Description: Those who agreed to download a mobile app for colonoscopic bowel preparation on their smartphones.
Study: NCT05639439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A
Description: Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B
Description: Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C
Description: Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)
Study: NCT04971512

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: Placebo to match EDP-514
Study: NCT05639439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D
Description: Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)
Study: NCT05684198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subcutaneous NPWT
Description: Following fascia closure, NPWT system will be inserted into subcutaneous tissue, continuous negative pressure of 120 mmHg will be applied.
Study: NCT05472740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 7000
Description: TENS device to be used in both the active and placebo groups

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS 7000
Description: TENS device to be used in both the active and placebo groups
Study: NCT04411654

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LY3884961
Description: Participants will receive a single dose of LY3884961 administered intracisternally.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LY3884961
Description: Participants will receive a single dose of LY3884961 administered intracisternally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Single IV pulse administered as concomitant medication.
Study: NCT06164600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Description: A powdered form of the first 6 hours bovine colostrum \[65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
Study: NCT06309433

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual energy x-ray absorptiometry
Description: Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual energy x-ray absorptiometry
Description: Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone
Study: NCT04411654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Single IV pulse administered as concomitant medication.
Study: NCT05444088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: intravenous infusion
Study: NCT06517511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor Oral Tablet [Xpovio]
Description: Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Protocol
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study: NCT06034431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ride Share
Description: The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes
Study: NCT05889741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 6.5cc of Normal Saline one time into the stellate ganglion.